A new study published in JSCAI has revealed a lower risk of cardiovascular events for patients with Type 1 diabetes (often ...

A new study published in the Journal of the Society for Cardiovascular Angiography & Interventions has revealed a lower risk ...

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help ...

Elkhorn Logan Valley Public Health Department’s Scale Down program will begin next month in Norfolk. This program is designed to help individuals adopt healthier lifestyles, lose weight and prevent th ...

Bariatric surgery is safe and induces substantial weight loss that reduces the need for diabetes medications, a Monash ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

"Yo-yo" dieting --- repeatedly losing and gaining weight -- can significantly increase risk of kidney disease among people ...

Use of a sodium-glucose cotransporter 2, or SGLT2, inhibitor combined with calorie restriction resulted in greater rates of type 2 diabetes remission compared with calorie restriction alone, according ...